Swiss National Bank
CPRX

Swiss National Bank’s Catalyst Pharmaceutical CPRX Stock Holding History

Swiss National Bank’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.93M Sell
220,600
-8,700
-4% -$257K ﹤0.01% 1254
2026
Q1 		$5.68M Hold
229,300
– – ﹤0.01% 1292
2025
Q4 		$5.35M Buy
229,300
+4,600
+2% +$102K ﹤0.01% 1315
2025
Q3 		$4.43M Buy
224,700
+3,400
+2% +$69.9K ﹤0.01% 1398
2025
Q2 		$4.8M Buy
221,300
+13,400
+6% +$316K ﹤0.01% 1325
2025
Q1 		$5.04M Sell
207,900
-2,200
-1% -$49.5K ﹤0.01% 1253
2024
Q4 		$4.38M Buy
210,100
+2,500
+1% +$53.7K ﹤0.01% 1413
2024
Q3 		$4.13M Sell
207,600
-1,200
-0.6% -$22.2K ﹤0.01% 1448
2024
Q2 		$3.23M Hold
208,800
– – ﹤0.01% 1549
2024
Q1 		$3.33M Buy
208,800
+19,700
+10% +$297K ﹤0.01% 1557
2023
Q4 		$3.18M Sell
189,100
-33,400
-15% -$457K ﹤0.01% 1579
2023
Q3 		$2.6M Buy
222,500
+4,000
+2% +$53.5K ﹤0.01% 1677
2023
Q2 		$2.94M Buy
218,500
+5,100
+2% +$73.4K ﹤0.01% 1637
2023
Q1 		$3.54M Sell
213,400
-22,500
-10% -$371K ﹤0.01% 1475
2022
Q4 		$4.39M Buy
235,900
+4,200
+2% +$64.7K ﹤0.01% 1400
2022
Q3 		$2.97M Hold
231,700
– – ﹤0.01% 1599
2022
Q2 		$1.62M Hold
231,700
– – ﹤0.01% 2064
2022
Q1 		$1.92M Buy
231,700
+14,300
+7% +$101K ﹤0.01% 2055
2021
Q4 		$1.47M Hold
217,400
– – ﹤0.01% 2240
2021
Q3 		$1.15M Hold
217,400
– – ﹤0.01% 2366
2021
Q2 		$1.25M Sell
217,400
-7,600
-3% -$39.2K ﹤0.01% 2373
2021
Q1 		$1.04M Buy
225,000
+5,700
+3% +$22.6K ﹤0.01% 2336
2020
Q4 		$732K Hold
219,300
– – ﹤0.01% 2401
2020
Q3 		$651K Hold
219,300
– – ﹤0.01% 2289
2020
Q2 		$1.01M Buy
219,300
+39,400
+22% +$177K ﹤0.01% 2094
2020
Q1 		$693K Buy
179,900
+2,600
+1% +$10.7K ﹤0.01% 2022
2019
Q4 		$665K Buy
177,300
+5,200
+3% +$24.3K ﹤0.01% 2328
2019
Q3 		$914K Hold
172,100
– – ﹤0.01% 2105
2019
Q2 		$661K Buy
+172,100
New +$743K ﹤0.01% 2324

Other funds holding CPRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Swiss National Bank's CPRX Position: Q2 2026 in Review

Swiss National Bank reduced its Catalyst Pharmaceutical (CPRX) stake by 3.8% in Q2 2026, selling an estimated $257K and leaving 220,600 shares worth $6.93M. The position accounts for ﹤0.01% of the portfolio, ranked #1254.

Swiss National Bank first reported a position in CPRX in Q2 2019 and has held it in 29 quarters since. 395 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

  • Swiss National Bank held 220,600 shares of Catalyst Pharmaceutical worth $6.93M as of Q2 2026.
  • Swiss National Bank sold 8,700 Catalyst Pharmaceutical shares in Q2 2026, an estimated $257K.
  • Catalyst Pharmaceutical made up ﹤0.01% of Swiss National Bank's portfolio in Q2 2026, its #1254 holding.
  • Swiss National Bank first reported a position in Catalyst Pharmaceutical in Q2 2019 and has held it in 29 quarters since.
  • 395 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on Swiss National Bank's 13F filing for Q2 2026, filed 11 Aug 2026.